OBI Pharma is a leading biopharmaceutical company dedicated to developing innovative therapeutic agents to address unmet medical needs. With a strong focus on cancer therapies, OBI Pharma is committed to bringing novel treatments to patients globally. Under the guidance of Chief Executive Officer, Dr.

Heidi Wang, OBI Pharma combines expertise in global executive management, regulatory affairs, and drug approvals across various therapeutic areas. Their pipeline includes promising candidates such as Adagloxad simolenin and OBI-866 vaccines, OBI-999 antibody-drug conjugate (ADC), and AKR1C3 enzyme inhibitors. OBI Pharma recently presented exciting data at the AACR 2023 Annual Meeting, showcasing the synergistic anti-tumor effects of OBI-999 in combination with pembrolizumab checkpoint inhibitor and their development of CAR T-cell cancer immunotherapy targeting Globo H.

With a dedicated and talented management team, OBI Pharma remains at the forefront of cutting-edge research and development in the field of oncology. For more information about their groundbreaking work and career opportunities, please visit their website